Our previous preclinical modeling suggested that efficient RAS activation in ER+ NF1-depleted breast cancers can promote tumor cell survival when ER signaling is blocked by fulvestrant, and the consequent fulvestrant resistance can be inhibited by binimetinib (9). The gene discussed is NF1; the disease is breast cancer.